^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    STLA101 Test

    Company:
    Stella Diagnostics
    Type:
    Laboratory Developed Test

    Details

    Evidence
    News
    The STLA101 panel consists of 8 proprietary biomarkers that may be predictive of carcinogenesis in precancerous esophageal tissue. STLA102 consists of biomarkers associated with increased efficacy of resistance to all of the FDA approved chemotherapies and targeted therapies for esophageal adenocarcinoma.
    Cancer:
    Esophageal Cancer